Scope of the Report
The report entitled “Global Bio CMO Market: Size, Trends & Forecasts (2018-2022)â€, provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the global biologics market by value, by top selling products, etc.
Growth of the overall global bio CMO market has been forecasted for the years 2017-2022, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.
Lonza Group, Boehringer Ingelheim, Samsung Biologics and Wuxi Biologics are key companies in the global bio CMO market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
Company Coverage
Lonza Group
Boehringer Ingelheim
Samsung Biologics
Wuxi Biologics
Executive Summary
Pharmaceutical industry comprise of discovering, developing, producing and marketing of drugs for medical use. World’s largest pharmaceutical firms are located in the North America, Europe and Japan. On the basis of technological platform, pharmaceutical drugs can be divided into small molecule or conventional drugs and large molecule or biologic drugs.
Biologics are made through biological processes and are generally injected. Biologics comprises of vaccines, blood or blood components, somatic cells, gene therapy, etc. Biologics are categorized into first-or second generation, depending on development period and cell line. Biosimilars are the biological that are similar, but not identical to the original product.
CMO or Contract Manufacturing Organization is a third party, which the pharmaceutical firms approach for the manufacturing of components of its product or whole of its product. Bio CMOs are typically used to provide secondary manufacturing coverage for the branded pharmaceutical industry. On the basis of production technology, bio CMOs can be divided into mammalian cell system and microbial system.
The global bio CMO market is expected to increase at a significant growth rate during the forecasted period (2017-2022). The global bio CMO market is supported by various growth drivers, such as increase in pharmaceutical industry, growth in use of biosimilars, potential biologics blockbusters, introduction of targeted therapins, grater outsourcing demand from global pharmas, etc. Yet, the market faces certain challenges, such as risk associated with CMOs, presence of in-house manufacturing facilities of big pharma companies, productivity issues with mammalian cell system, etc.
1. Executive Summary
2. Introduction
2.1 Pharmaceutical Industry Overview
2.1.1 Segments of Pharmaceutical Industry (Drugs)
2.2 Biotechnology/Biologics Overview
2.3 Biosimilar Overview
2.4 Biologics/ Biosimilar Manufacturing
2.5 Bio CMO Overview
2.5.1 Comparison: In-House Vs CMO Production
3. Global Market Analysis
3.1 Global Biologics Market: An Analysis
3.1.1 Global Biologics Market by Value
3.1.2 Global Biologics Market by Top Selling Drugs
3.1.3 Global Biologics Market by Product in Development
3.1.4 Global Biologics Manufacturing Market by Value
3.2 Global Bio CMO Market: An Analysis
3.2.1 Global Bio CMO Market by Penetration Rate
3.2.2 Global Bio CMO Market by Value
3.2.3 Global Bio CMO Market by Capacity
3.2.4 Global Bio CMO Market by Segments
3.2.5 Global Bio CMO Market by Manufacturing Processes
3.3 Global Bio CMO Market Segment Analysis
3.3.1 Global Bio CMO Downstream Process Market by Value
3.3.2 Global Bio CMO Upstream Process Market by Value
3.3.3 Global Bio CMO Fill and Finish Process Market by Value
4. Competitive Landscape
4.1 Global Bio CMO Market by Players
4.2 Global Bio CMO Players by Capacity
5. Company Profiles
5.1 Lonza
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategy
5.2 Boehringer Ingelheim
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategy
5.3 Samsung Electronics (Samsung Biologics)
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategy
5.4 Wuxi Biologics
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategy
List of Figures
Figure 1: History of Pharmaceutical Industry
Figure 2: Pharmaceutical Industry Segments
Figure 3: Global Biologics Market by Value; 2016-2022E (US$ Billion)
Figure 4: Global Biologics Market by Products in Development; 2015-2016
Figure 5: Global Biologics Manufacturing Market by Value; 2012-2016 (US$ Billion)
Figure 6: Global Biologics Manufacturing Market by Value; 2017-2022E (US$ Billion)
Figure 7: Global Bio CMO Market by Penetration Rate; 2012-2016 (%)
Figure 8: Global Bio CMO Market by Penetration Rate; 2017-2022E (%)
Figure 9: Global Bio CMO Market by Value; 2012-2016 (US$ Billion)
Figure 10: Global Bio CMO Market by Value; 2017-2022 (US$ Billion)
Figure 11: Global Bio CMO Market by Capacity; 2014-2016 (KL)
Figure 12: Global Bio CMO Market by Capacity; 2017-2022E (KL)
Figure 13: Global Bio CMO Market by Segments; 2015
Figure 14: Global Bio CMO Market by Manufacturing Processes; 2016
Figure 15: Global Bio CMO Downstream Process Market by Value; 2012-2016 (US$ Billion)
Figure 16: Global Bio CMO Downstream Process Market by Value; 2017-2022E (US$ Billion)
Figure 17: Global Bio CMO Upstream Process Market by Value; 2012-2016 (US$ Billion)
Figure 18: Global Bio CMO Upstream Process Market by Value; 2017-2022E (US$ Billion)
Figure 19: Global Bio CMO Fill and Finish Process Market by Value; 2012-2016 (US$ Billion)
Figure 20: Global Bio CMO Fill and Finish Process Market by Value; 2017-2022E (US$ Billion)
Figure 21: Global Bio CMO Market Revenue by Players; 2016
Figure 22: Global Bio CMO Players by Capacity; 1H16 (KL)
Figure 23: Lonza Group Sales; 2012-2016 (US$ Billion)
Figure 24: Lonza Group Sales by Region; 2016
Figure 25: Lonza Group Sales by Segments; 2016
Figure 26: Boehringer Ingelheim Sales; 2012-2016 (US$ Billion)
Figure 27: Boehringer Ingelheim Sales by Segments; 2016
Figure 28: Boehringer Ingelheim Sales by Region; 2016
Figure 29: Samsung Electronics Segments Overview
Figure 30: Samsung Electronics Ownership Structure
Figure 31: Samsung Electronics and Biologics Revenue; 2012-2016 (US$ Billion)
Figure 32: Samsung Electronics Revenue by Segments; 2016
Figure 33: Wuxi Biologics Revenue; 2014-2016 (US$ Million)
Figure 34: Wuxi Biologics Revenue by Services; 2016
Figure 35: Wuxi Biologics Revenue by Fee Model; 2016
Table 1: Chemical Drugs v/s 1st Generation Biologics v/s 2nd Generation Biologics
Table 2: US Approved Biosimilars
Table 3: Comparison: In-House Vs CMO Production
Table 4: Top Selling Biologics Drugs; 2016
